Back to results
US 2020/0263258 A1Published application
Assessing and treating mammals having polyps
AssigneeMayo Foundation for Medical Education and Research
InventorsLisa A. Boardman, Brooke R. Druliner
Life of this patent
Estimating the term…
Abstract
This document relates to methods and materials for assessing and/or treating mammals (e.g., humans) having one or more polyps (e.g., one or more colon polyps). For example, this document provides methods and materials for determining if a polyp (e.g., a polyp within a mammal having one or more polyps) is likely to recur and/or likely to progress to a cancer. This document also provides methods and materials for treating a mammal having one or more polyps.
Claims17
A method for treating a mammal having one or more colon polyps, wherein said method comprises:
- (a) identifying at least one polyp from the mammal as having a molecular profile comprising one or more modifications in one or more nucleic acid sequences selected from the group consisting of E2F8, COL2A1, GREM1, COL6A3, SCARF2, STK33, ERBB3, P2RY6, IGSF22, CNTN4, EFNB3, ZNF579, NEB, HES1, STX8, NUP210, MEGF10, GPC1, KIAA0825, GRIN2C, BRSK2, ARIH2, SATB1, SCN5A, PPARG, RARG, SOCS3, HHIP, RGMA, ANKRD36, NPC1L1, TNNC2, PRKACB, MED7, ZNF141, ALPPL2, TRRAP, TK1, C11orf63, RIMS2, BCL2L10, C4orf33, GYLTL1B, C1orf86, ZNF480, TAF1L, GBGT1, SST, FBN1, EBF4, NPW, TNC, FGF8, COG6, NOX5, ZNF470, PLXDC1, ATHL1, SNCAIP, IGF2, KMT2B, CRYBA2, IL11, CD248, NACAD, ACSL6, A1BG, CABP7, THRB, NUAK1, MATK, FARP1, CACNA1I, TRPC1, LYL1, RPH3A, KCNN2, CLYBL, SLITRK2, AHSA2, CHRD, CIT, DPY19L2P2, IGDCC3, COL12A1, HEBP1, COL4A3, ISLR, DNAH9, CDH3, ST6GALNAC5, ZNF599, GPRIN2, TANC2, SPEG RASAL3, HMCN1, TRPV3, CR2, OTOP3, COL13A1, CPLX1, DUSP2, MT1JP, NOTCH3, ZNF726, ROBO3, CCK, SLC5A7, TSPY26P, FADS1, PLEKHG2, CACNA1H, LILRA1, COL5A2, ZNF836, FES, RIMS1, VANGL2, MUC4, BAIAP3, PLEKHH2, GPR98, COL11A2, APC, TP53, TTN, KRAS, FBXW7, PIK3CA, CTNNB1, KIAA1804, SMAD2, SMAD4, CXCL5, GREM1, IGF2, CTGF, PLAU, FES, HES1, ERBB3, and E2F8 nucleic acid sequences, wherein said one or more modifications are selected from the group consisting of a somatic variation in a nucleic acid sequence, altered expression of a nucleic acid sequence, altered methylation of a nucleic acid sequence, and combinations thereof, and
- (b) administering a colon polyp treatment to said mammal under conditions wherein the number of colon polyps within said mammal is reduced.
A method for treating a mammal having one or more colon polyps, wherein said method comprises:
- administering a colon polyp treatment to a mammal identified as having at least one polyp having a molecular profile comprising one or more modifications in one or more nucleic acid sequences selected from the group consisting of E2F8, COL2A1, GREM1, COL6A3, SCARF2, STK33, ERBB3, P2RY6, IGSF22, CNTN4, EFNB3, ZNF579, NEB, HES1, STX8, NUP210, MEGF10, GPC1, KIAA0825, GRIN2C, BRSK2, ARIH2, SATB1, SCN5A, PPARG, RARG, SOCS3, HHIP, RGMA, ANKRD36, NPC1L1, TNNC2, PRKACB, MED7, ZNF141, ALPPL2, TRRAP, TK1, C11orf63, RIMS2, BCL2L10, C4orf33, GYLTL1B, C1orf86, ZNF480, TAF1L, GBGT1, SST, FBN1, EBF4, NPW, TNC, FGF18, COG6, NOX5, ZNF470, PLXDC1, ATHL1, SNCAIP, IGF2, KMT2B, CRYBA2, IL11, CD248, NACAD, ACSL6, A1BG, CABP7, THRB, NUAK1, MATK, FARP1, CACNA1I, TRPC1, LYL1, RPH3A, KCNN2, CLYBL, SLITRK2, AHSA2, CHRD, CIT, DPY19L2P2, IGDCC3, COL12A1, HEBP1, COL4A3, ISLR, DNAH9, CDH3, ST6GALNAC5, ZNF599, GPRIN2, TANC2, SPEG, RASAL3, HMCN1, TRPV3, CR2, OTOP3, COL13A1, CPLX1, DUSP2, MT1JP, NOTCH3, ZNF726, ROBO3, CCK, SLC5A7, TSPY26P, FADS1, PLEKHG2, CACNA1H, LILRA1, COL5A2, ZNF836, FES, RIMS1, VANGL2, MUC4, BAIAP3, PLEKHH2, GPR98, COL11A2, APC, TP53, TTN, KRAS, FBXW7, PIK3CA, CTNNB1, KIAA1804, SMAD2, SMAD4, CXCL5, GREM1, IGF2, CTGF, PLAU, FES, HES1, ERBB3, and E2F8 nucleic acid sequences, wherein said one or more modifications are selected from the group consisting of a somatic variation in a nucleic acid sequence, altered expression of a nucleic acid sequence, altered methylation of a nucleic acid sequence, and combinations thereof.
A method for treating a mammal having one or more colon polyps, wherein said method comprises:
- (a) identifying at least one polyp from the mammal as having a molecular profile comprising one or more modifications in one or more nucleic acid sequences selected from the group consisting of E2F8, COL2A1, GREM1, COL6A3, SCARF2, STK33, ERBB3, P2RY6, IGSF22, CNTN4, EFNB3, ZNF579, NEB, HES1, STX8, NUP210, MEGF10, GPC1, KIAA0825, GRIN2C, BRSK2, ARIH2, SATB1, SCN5A, PPARG, RARG, SOCS3, HHIP, RGMA, ANKRD36, NPC1L1, TNNC2, PRKACB, MED7, ZNF141, ALPPL2, TRRAP, TK1, C11orf63, RIMS2, BCL2L10, C4orf33, GYLTL1B, C1orf86, ZNF480, TAF1L, GBGT1, SST, FBN1, EBF4, NPW, TNC, FGF18, COG6, NOX5, ZNF470, PLXDC1, ATHL1, SNCAIP, IGF2, KMT2B, CRYBA2, IL11, CD248, NACAD, ACSL6, A1BG, CABP7, THRB, NUAK1, MATK, FARP1, CACNA1I, TRPC1, LYL1, RPH3A, KCNN2, CLYBL, SLITRK2, AHSA2, CHRD, CIT, DPY19L2P2, IGDCC3, COL12A1, HEBP1, COL4A3, ISLR, DNAH9, CDH3, ST6GALNAC5, ZNF599, GPRIN2, TANC2, SPEG RASAL3, HMCN1, TRPV3, CR2, OTOP3, COL13A1, CPLX1, DUSP2, MT1JP, NOTCH3, ZNF726, ROBO3, CCK, SLC5A7, TSPY26P, FADS1, PLEKHG2, CACNA1H, LILRA1, COL5A2, ZNF836, FES, RIMS1, VANGL2, MUC4, BAIAP3, PLEKHH2, GPR98, COL11A2, APC, TP53, TTN, KRAS, FBXW7, PIK3CA, CTNNB1, KIAA1804, SMAD2, SMAD4, CXCL5, GREM1, IGF2, CTGF, PLAU, FES, HES1, ERBB3, and E2F8 nucleic acid sequences, wherein said one or more modifications are selected from the group consisting of a somatic variation in a nucleic acid sequence, altered expression of a nucleic acid sequence, altered methylation of a nucleic acid sequence, and combinations thereof,
- (b) administering a colon polyp treatment to said mammal under conditions wherein the number of colon polyps within said mammal is reduced;
- and
- (c) administering a cancer treatment to said mammal.
1 more element
A method for treating a mammal having one or more colon polyps, wherein said method comprises:
- administering a colon polyp treatment to a mammal identified as having at least one polyp having a molecular profile comprising one or more modifications in one or more nucleic acid sequences selected from the group consisting of E2F8, COL2A1, GREM1, COL6A3, SCARF2, STK33, ERBB3, P2RY6, IGSF22, CNTN4, EFNB3, ZNF579, NEB, HES1, STX8, NUP210, MEGF10, GPC1, KIAA0825, GRIN2C, BRSK2, ARIH2, SATB1, SCN5A, PPARG, RARG, SOCS3, HHIP, RGMA, ANKRD36, NPC1L1, TNNC2, PRKACB, MED7, ZNF141, ALPPL2, TRRAP, TK1, C11orf63, RIMS2, BCL2L10, C4orf33, GYLTL1B, C1orf86, ZNF480, TAF1L, GBGT1, SST, FBN1, EBF4, NPW, TNC, FGF18, COG6, NOX5, ZNF470, PLXDC1, ATHL1, SNCAIP, IGF2, KMT2B, CRYBA2, IL11, CD248, NACAD, ACSL6, A1BG, CABP7, THRB, NUAK1, MATK, FARP1, CACNA1I, TRPC1, LYL1, RPH3A, KCNN2, CLYBL, SLITRK2, AHSA2, CHRD, CIT, DPY19L2P2, IGDCC3, COL12A1, HEBP1, COL4A3, ISLR, DNAH9, CDH3, ST6GALNAC5, ZNF599, GPRIN2, TANC2, SPEG, RASAL3, HMCN1, TRPV3, CR2, OTOP3, COL13A1, CPLX1, DUSP2, MT1JP, NOTCH3, ZNF726, ROBO3, CCK, SLC5A7, TSPY26P, FADS1, PLEKHG2, CACNA1H, LILRA1, COL5A2, ZNF836, FES, RIMS1, VANGL2, MUC4, BAIAP3, PLEKHH2, GPR98, COL11A2, APC, TP53, TTN, KRAS, FBXW7, PIK3CA, CTNNB1, KIAA1804, SMAD2, SMAD4, CXCL5, GREM1, IGF2, CTGF, PLAU, FES, HES1, ERBB3, and E2F8 nucleic acid sequences, wherein said one or more modifications are selected from the group consisting of a somatic variation in a nucleic acid sequence, altered expression of a nucleic acid sequence, altered methylation of a nucleic acid sequence, and combinations thereof, and
- administering a cancer treatment to said mammal.
Dependencies are inferred from the claim text.